Clinical Trials

132 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

63 enrolled

Adenocarcinoma of Lung

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

450 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05547737 2022-09-21

NSCLC

Unknown

500 enrolled

NSCLC

NCT05532527 2022-09-08

NSCLC

Phase NA Unknown

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04749394 2022-08-16

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

42 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05330065 2022-04-15

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Phase 1/2 Unknown

55 enrolled

Pleural Effusion, Malignant

NCT04901754 2021-12-08

CAMERA

38 enrolled

Small Cell Lung Carcinoma

NCT04291092 2021-09-10

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

63 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04943029 2021-09-02

NEOSUN

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05001412 2021-08-12

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Phase 1 Unknown

36 enrolled

Extensive Stage Small Cell Lung Cancer

NCT04950400 2021-07-06

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Phase NA Unknown

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04541251 2021-06-23

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04828395 2021-05-11

F&C

65 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03668496 2021-03-15

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

390 enrolled

Lung Neoplasms

NCT04793139 2021-03-11

Efficacy and Safety of Camrelizumab in Real-World Prospective Study

Unknown

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04790539 2021-03-10

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

71 enrolled

Extensive Stage Small Cell Lung Cancer

NCT04768075 2021-02-24

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04683198 2020-12-24

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

69 enrolled

Small Cell Lung Carcinoma

NCT04631146 2020-11-17

Efficacy and Safety of Camrelizumab in Real-World Study

Unknown

450 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04102982 2020-11-02

MWA in NSCLC

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04506242 2020-09-09

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

74 enrolled

NSCLC

NCT04453930 2020-07-01

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

60 enrolled

Small Cell Lung Carcinoma

NCT04425135 2020-06-11

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

59 enrolled

Lung Neoplasms

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

762 enrolled

PD-L1 Positive Non-small Cell Lung Cancer

NCT04303130 2020-03-10

Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

52 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03557411 2020-02-05

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

42 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04167774 2019-11-22

Compass-001

62 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04133337 2019-10-21

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Phase 1/2 Unknown

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04108013 2019-09-27

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

38 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03755115 2019-01-16

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

40 enrolled

Small Cell Lung Cancer Extensive Stage

NCT03601598 2018-07-26

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

Phase 1/2 Unknown

41 enrolled

CRC

NCT03527251 2018-05-30

SEQUENCE

Phase 1 Unknown

10 enrolled